Sageworth Trust’s AstraZeneca AZN Stock Holding History

Sageworth Trust’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-1,376	Closed	-$253K	–	176
2025 Q4	$253K	Sell	1,376 -1,196	-47%	-$210K	0.01%	119
2025 Q3	$395K	Buy	+2,572	New	+$389K	0.02%	185
2023 Q2	–	Sell	-294	Closed	-$40.7K	–	115
2023 Q1	$40.7K	Buy	+294	New	+$39.6K	﹤0.01%	152
2019 Q2	–	Sell	-796	Closed	-$64K	–	181
2019 Q1	$64K	Buy	+796	New	+$62.7K	0.01%	65

Other funds holding AZN

Investor AB Stockholm, Sweden $15.1B AUM 29.02% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

VAM

Vanguard Asset Management London, Ec4n 8af $117B AUM

Sageworth Trust's AZN Position: Q1 2026 in Review

Sageworth Trust sold out of AstraZeneca (AZN) in Q1 2026, closing a stake of 1,376 shares — an estimated $253K sold.

Sageworth Trust first reported a position in AZN in Q1 2019 and held it in 4 quarters. The position peaked at $395K in Q3 2025. 1,377 funds tracked by Wall St. Rank hold AZN as of Q1 2026.

Sageworth Trust reported no remaining AstraZeneca position as of Q1 2026 after selling out during the quarter.
Sageworth Trust sold 1,376 AstraZeneca shares in Q1 2026, an estimated $253K.
Sageworth Trust first reported a position in AstraZeneca in Q1 2019 and held it in 4 quarters.
Sageworth Trust's AstraZeneca position peaked at $395K in Q3 2025.
1,377 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2026.

Based on Sageworth Trust's 13F filing for Q1 2026, filed 29 Apr 2026.